Myriad Genetics, Inc.

Greetings and welcome to the Myriad Genetics 4th Quarter 2022 Financial Earnings Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we'll conduct a question-and-answer session. At that time, if you have a question, please press the 1 followed by the 4 on your telephone. Should you require operator assistance at any time, please press star 0. As a reminder, this conference is being recorded Tuesday, February 28, 2023. I'd now like to turn the call over to Matt Fagallo. Please go ahead.

Okay, good afternoon, and welcome to the Myriad Genetics fourth quarter and full year 2022 earnings call. During the call, we will review financial results we released today, and afterwards, we will host a Q&A session. Our quarterly earnings release was issued this afternoon on Form 8K and can be found on our website at investor.myriad.com. I'm Matt Scalab, Senior Vice President of Investor Relations, and on the call with me today are Paul Diaz, our President and Chief Executive Officer, Ryan Rigsby, our Chief Financial Officer, Nicole Lambert, our Chief Operating Officer, and Mark Verratti, our Chief Commercial Officer. This call can be heard live via webcast at investor.mary.com, and a recording will be archived in the investor section of our website along with this slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or future financial performance of the company. These statements are based on the management's current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements. With that, I'll now turn the call over to Paul.

Thanks, Matt. Good afternoon, everyone, and thank you for joining us. On today's call, we will discuss highlights from the fourth quarter and full year. We will also provide updates on the strategic initiatives that are driving our long-term growth plan. First, I want to thank all of our teammates at Myriad for their hard work and dedication this year to advance our mission and our vision to make genetic testing and precision medicine more accessible to help people take more control of their health and enable providers to better detect, treat, and prevent disease. With so many positive changes happening across the organization, I'm incredibly proud of how our teams have kept their focus on our patients and providers. Myriad Genetics ended the year with a strong fourth quarter performance. Total revenue grew 11% year over year, driven by double-digit volume growth in both MyRisk hereditary cancer testing and GeneSight. We believe these results reflect the market's growing response to our commercial initiatives, and we are confident in our ability to achieve our financial guidance, as well as reach profitability and positive operating cash flow in Q4 of this year. Additionally, our continued commercial execution, robust pipeline, strong capital structure, and top-tier talent will fuel our long-term growth even further. Transitioning to slide five, we closed and have successfully integrated the acquisition of Gateway Genomics and are excited to be working with Chris Jacobs, its CEO, and the entire Gateway team. The Sneak Peek early gender DNA test continues to perform well across all of its commercial channels. In 2023, we will continue to look for cross-selling opportunities with other Myriad products and aim to increase Sneak Peek's attachment rate to our NIPS test prequel without disrupting Sneak Peek's performance. We entered 2023 with a tremendous amount of positive momentum as we take advantage of our improved commercial capabilities with an increased focus on sales operations and execution. GeneSight has been an incredibly successful example of this, and we plan to extend elements of the GeneSight and Sneak Peek direct-to-consumer commercial models across other businesses, primarily in women's health. I also want to point out what a great job our teams have done in listening to our patients and providers. We have re-approached the way we have engaged with customers, and they are starting to notice. A great example being our move to an open source data strategy with ClinVar, which is something that the genetic counselor community has been quite vocal about. I'll let Nicole talk more about this and give more examples later during the call. Nicole will also touch on how this increased engagement with patients and providers has significantly changed and improved the perception of myriad genetics among our customers. Keeping patients and providers at the center of everything we do is starting to pay dividends, and we are excited about finding ways to make it easier to do business with us. Everything from increased price transparency and affordability for patients to the rollout of initiatives like our EMR integrations with Epic and our unified ordering portal, along with improvements to MiriComplete, our customized suite of services and workflow solutions. Please check out our substantially upgraded website when you have a chance as well. These are just a few examples of the things that we are excited about here at Myriad Genetics. And we have a number of new hires to the franchise, which will be instrumental in bringing these initiatives to their full potential. With that, I'll turn the call over to Chief Commercial Officer Mark Verratti, who will speak to our increased focus on sales operations and execution. Mark?